colorectal cancer cells. In colorectal tumour xenografts and APC min/+ transgenic mice, administration of salinomycin significantly reduced tumour growth and the expression of CSC-related Wnt target genes including LGR5.
Conclusions and Implications: Our study suggested that salinomycin could suppress the growth of colorectal cancer by disrupting the β-catenin/TCF complex and thus may be a promising agent for colorectal cancer treatment.
| INTRODUCTION
Colorectal cancer is the third most common malignancy and a major cause of cancer-related death worldwide. About 90% of colorectal cancers carry somatic mutations in Wnt signalling component genes such as the adenomatous polyposis coli (APC) and β-catenin (CTNNB1) genes, resulting in aberrant activation of the Wnt signalling pathway (Cancer Genome Atlas, 2012; Nusse & Clevers, 2017; Zhan, Rindtorff, & Boutros, 2017; Zhang & Shay, 2017) . The protein β-catenin is a central component of the canonical Wnt signalling pathway. The stability of β-catenin is controlled by a cytoplasmic destruction complex that is composed of the APC tumour suppressor, the scaffolding protein Axin, glycogen synthase kinase 3β (GSK3β), and casein kinase 1 (CK1). APC binding to β-catenin leads to ubiquitin-mediated β-catenin degradation. Loss of APC function due to mutations stabilizes β-catenin, resulting in an accumulation of β-catenin in the cytosol as well as the nucleus, where it acts as a coactivator for the T-cell factor/lymphoid enhancing factor (TCF/ LEF) transcription factors to activate the transcription of Wnt target genes (Clevers & Nusse, 2012) . Indeed, nuclear β-catenin accumulation was detected in more than 80% of colorectal tumours and was significantly correlated with poor prognosis (Baldus et al., 2004; Sebio, Kahn, & Lenz, 2014; Wanitsuwan, Kanngurn, Boonpipattanapong, Sangthong, & Sangkhathat, 2008) .
Wnt/β-catenin signalling is a crucial pathway of cancer stem cell (CSC) development. Its aberrant activation is essential for maintaining the self-renewal capacities of CSCs (de Sousa, Vermeulen, Richel, & Medema, 2011; Zeki, Graham, & Wright, 2011) . There is good evidence for the presence of CSCs in colorectal cancer (Munro, Wickremesekera, Peng, Tan, & Itinteang, 2018) and CSCs are responsible for the tumour initiation, proliferation, chemoresistance, metastasis, and tumour recurrence. Targeting the CSC population may provide a new therapeutic strategy for colorectal cancer (Munro et al., 2018) .
Salinomycin, a monocarboxylic polyether antibiotic isolated from
Streptomyces albus, is known to be an inhibitor of human CSCs. This compound selectively killed breast CSCs, at least 100 times more effectively than paclitaxel, in mice (Gupta et al., 2009) . Salinomycin also selectively inhibited CSCs in a range of cancers, including breast, lung, gastric, osteosarcoma, squamous cell carcinoma, prostate, pancreatic, and colorectal cancers (Zhang, Li, Liu, Ma, & Chen, 2016) .
However, the molecular mechanisms by which salinomycin targets
CSCs is poorly understood. Several potential mechanisms have been suggested (Dewangan, Srivastava, & Rath, 2017) , including suppression of the ATP-binding cassette (ABC) transporter (Fuchs, Daniel, Sadeghi, Opelz, & Naujokat, 2010; Kim et al., 2012) and blocking of pathways implicated in cancer such as Akt (Kuo et al., 2012) , Wnt (D. , Hedgehog (Y. Lu et al., 2015) , and Notch (Zhou et al., 2014) .
The anti-cancer activity of salinomycin against colorectal cancer has been demonstrated both in vitro and in vivo. Salinomycin selectively reduced the CD133 + cell subpopulations of colorectal cancer cells (Dong et al., 2011) . Treatment with this compound decreased LRP6 protein levels and inhibited LRP6-phosphorylation in human CRC cells, resulting in the down-regulation of the Wnt target genes Fibronectin and leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5; Klose et al., 2016) . These results suggest that the Wnt/β-catenin pathway was involved in the anti-cancer effect of salinomycin on colorectal cancers. As LRP6 is an upstream regulator of the Wnt pathway, it is questionable whether inhibiting LRP6 function is strong enough to interfere with Wnt/β-catenin signalling in human CRC cells exhibiting APC or β-catenin mutations. In the present study, we identified a novel mechanism for the inhibition of Wnt/β-catenin signalling by salinomycin in colorectal cancer.
Salinomycin could inhibit Wnt/β-catenin signalling by disrupting the association between β-catenin and TCF4E. In colorectal CSC xenografts, APC min/+ mice, and patient-derived colorectal tumour xenografts, salinomycin treatment significantly reduced tumour growth and the expression of CSC-related Wnt target genes including LGR5.
What is already known
• Salinomycin is a potent inhibitor of cancer stem cells.
• Salinomycin could inhibit Wnt/β-catenin signalling through targeting Wnt/LRP6 complex.
What this study adds
• Salinomycin could suppress the colorectal cancer growth by disrupting the β-catenin/TCF complex.
What is the clinical significance
• Salinomycin may be a promising therapeutic agent for colorectal cancers with APC or β-catenin mutation. 
| Real-time PCR analyses
Total RNA was extracted using RNAiso Plus (TaKaRa Cat# 9109, Kusatsu, Shiga, Japan) and then reverse-transcribed into cDNA with the same RNA concentration for each sample using the Primescript RT Reagent Kit (TaKaRa Cat# RR037A, Kusatsu, Shiga, Japan) according to the manufacturer's instructions. Prepared cDNA was then subjected to quantitative PCR analysis using an ABI Prism 7300
Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) with 2× SYBR Green qPCR Master Mix (Bimake Cat# B21203, Houston, TX, USA). Real-time PCR assays were performed to quantify mRNA levels of human Axin2, CD44, cyclin D1, DKK1, c-Myc, LEF1,
LGR5, and Sox2 genes. Table S1 .
| Immunoblot analyses
The antibody-based procedures used in this study comply with the recommendations made by the British Journal of Pharmacology . Cells or tumour tissues were lysed in lysis buffer containing 0.1-M Tris-HCl (pH 7.0), 2% SDS, 10% glycerol, 0.1-mM DTT, 1-mM EDTA, 1-mM EGTA, 2.5-mM sodium pyrophosphate, 1-mM β-glycerol phosphate, 1-mM sodium orthovanadate, 2 μg·ml −1 leupeptin, and 1-mM PMSF, followed by sonication. Proteins were fractionated by SDS-PAGE and transferred to PVDF membranes (Cat# ISEQ00005, Millipore, Burlington, MA, USA).
Western blotting was performed with the following primary antibodies: anti-β-catenin (1:2 Imaging System (Tanon 5200, Shanghai, China). All immunoblot assays were performed using five independent samples. Densitometric analysis was carried out using the Quantity One 1-D Analysis Software, and the quantification results were normalized to the loading control.
| Co-immunoprecipitation
Total protein lysate of cells or tumour tissues was extracted with lysis buffer (20-mM Tris-HCl, pH 7.4, 150-mM NaCl, 1-mM EDTA, 1-mM EGTA, 1% Triton X-100, 2.5-mM sodium pyrophosphate, 1-mM β-glycerol phosphate, 1-mM sodium orthovanadate, 2 μg·ml 
| Chromatin immunoprecipitation assay
The chromatin immunoprecipitation (ChIP) assay was performed using the ChIP-IT Express Enzymatic Chromatin Immunoprecipitation Kit (Active Motif Cat# 53035) according to the manufacturer's instructions. The eluted DNA was amplified by PCR with the primers as previous indicated (Fang et al., 2016 
| Immunofluorescence staining
Immunofluorescence staining was performed as previously described 2.9 | Anchorage-independent growth assays A six-well plate was pre-coated with 1.5-ml 0.7% agar in a complete medium per well. The cells were harvested, suspended in 0.35% agar in a complete medium with the indicated amounts of salinomycin and then plated in triplicate onto the pretreated six-well plate (1.5-ml medium with 3,000 cells per well). The cells were then cultured in a humidified incubator at 37°C with 5% CO 2 for 2 weeks. Colonies were photographed following staining with crystal violet, and only those colonies larger than 0.05-mm were counted. Each treatment was performed in six replicates.
2.10 | Sphere formation assays Three days later, mice were randomly divided into two groups (n = 6 per group) and treated with the vehicle (0.8% DMSO/12%
Cremophor/8% ethanol in normal saline; n = 6) or 5 mg·kg
salinomycin in vehicle (n = 6) by intraperitoneal injection every 3 days.
Tumour size and body weight were measured every 3 days. After treatment for 1 month, mice were killed, and the tumours were dissected, weighed, and photographed.
Twelve 8-week-old male B6-APC min/+ mice were randomly divided into two groups (n = 6) and treated with the vehicle (0.8% DMSO/12%
Cremophor/8% ethanol in normal saline) or 5 mg·kg −1 salinomycin in vehicle twice weekly by intraperitoneal injection. Animals were weighed and checked weekly. At the age of 14 weeks, the mice were killed. The colon was collected and photographed before being fixed in buffered formalin.
Establishment of patient-derived colorectal tumour xenografts (PDTXs) was performed as previous described (Gao et al., 2015) .
Briefly, five patient-derived colorectal tumour pieces were implanted subcutaneously into the five 8-week-old male NPG mice. After treatment for 36 days, the mice were killed, and the tumour tissues were collected and weighed before being fixed in buffered formalin.
| Histological analyses
As described previously, formalin-fixed tumours were embedded with paraffin and sectioned; after which, immunohistochemistry and H&E staining were performed. Immunohistochemistry was performed using the following primary antibodies: anti-human Ki-67 
| Data and statistical analysis
The data and statistical analysis comply with the recommendations of the British Journal of Pharmacology on experimental design and analysis in pharmacology (Curtis et al., 2018) . All experiments were randomized and blinded. The normal probability plot was used to examine data distributions. Student's t test was applied when the data showed normal distribution. Statistical analyses were carried out with GraphPad prism7.00 software (GraphPad, RRID: SCR_000306). The data were analysed by Student's t test or oneway ANOVA followed by Dunnett's t test. Results are presented as mean ± SD. Differences at P < .05 were considered statistically significant.
| Materials
Salinomycin was obtained from Sigma-Aldrich (Cat # 563080-M). The
SuperTopFlash reporter vector was kindly provided by Karl Willert (University of California at San Diego, San Diego, CA, USA). The pDKK4-Luc reporter was constructed by cloning a DKK4 promoter region (−542 to −1) into the luciferase reporter vector pGL3-basic (Su et al., 2018) . The expression plasmids encoding β-catenin, LEF1, TCF4E, and β-galactosidase (β-gal) have been described previously (Wang et al., 2016) . The expression plasmid encoding N-terminal mutant of β-catenin (β-catenin 4A) was generated by site-directed mutagenesis (Easy Mutagenesis System, Transgen Biotech Cat# FM111-02) according to the manufacturer's instructions, The resulting plasmid was designated as pcDNA3/β-catenin 4A in which N-terminal residues Ser-33, Ser-37, Thr-41, and Ser-45 have been mutated to Ala.
GST-tagged β-catenin, GST-tagged β-catenin (134-668), and Histagged TCF4E (1-79) were constructed as previously reported (Fang et al., 2016) .
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander, Christopoulos et al., 2017; Alexander, Fabbro et al., 2017; . The luciferase values were normalized to β-gal activities. Each treatment was performed in six replicates. Values shown are means ± SD (n = 6). *P < .05, significantly different from the vehicle control; one-way ANOVA followed by Dunnett's t test.
3.2 | Salinomycin has little effect on the localization and the expression level of β-catenin in colorectal cancer cells
We further evaluated the effect of salinomycin on the localization and the expression level of β-catenin in colorectal cancer cells.
SW480 and HCT116 cells were treated with increasing concentrations of salinomycin (0.25-5 μM) for 24 hr. As shown in Figure 2a ,b, salinomycin had little effect on the expression level of β-catenin in both cell lines. Additionally, immunofluorescence staining showed that salinomycin did not affect the localization of β-catenin in colorectal cancer cells (Figure 2c,d ).
3.3 | Salinomycin disrupts the association between β-catenin and TCF4E
To assess whether salinomycin affects β-catenin binding to the Wnt target gene promoter, the ChIP assay was used to detect β-catenin binding to the promoters of two known Wnt target genes, Axin2 and c-Myc, in SW480 cells. As shown in Figure 3a , salinomycin significantly reduced β-catenin binding to Axin2 and c-Myc promoters ( Figure 3a ).
As DNA-bound TCF/LEF transcription factors are required to recruit β-catenin to a promoter, we investigated the effect of salinomycin on the interaction between β-catenin and TCF4E or LEF1 using immunoprecipitation. Expression plasmids for Flag-β-catenin 4A and TCF4E-V5 (Figure 3b ) or LEF1-V5 ( Figure 3c ) were transfected into HEK293T cells, and cell extracts were collected for affinity purification by anti-Flag M2 agarose. As shown in Figure 3b , c, Flag-β-catenin 4A was specifically coprecipitated with TCF4E-V5 or LEF1-V5, and the interactions were dose-dependently inhibited after salinomycin treatment (Figure 3b,c) .
We then examined the effect of salinomycin on the interaction of endogenous β-catenin and TCF4E proteins in colorectal cancer cells.
SW480 (Figure 3d To further confirm the inhibitory effect of salinomycin on the interaction between β-catenin and TCF4E, a GST pull-down assay was performed. The expression plasmids for GST-tagged full-length β-catenin respectively. GST-β-catenin and GST-β-catenin (134-668) were purified with GST-Sepharose and incubated with purified His-TCF4E
(1-79). The results showed that the full-length β-catenin (Figure 3g) or armadillo repeat domain of β-catenin ( Figure 3h ) interacted with the N-terminal region of TCF4E and addition of salinomycin dosedependently inhibited the interaction between two proteins.
| Salinomycin suppresses the transcriptional activity mediated by β-catenin/LEF1 or β-catenin/ TCF4E
To test the effect of salinomycin on the transcriptional activity induced by β-catenin/LEF1 or β-catenin/TCF4E, the pDKK4-Luc (d) and (e). Each treatment was performed in six replicates. Individual values are shown with means ± SD (n = 6). *P < .05, significantly different from the vehicle control; one-way ANOVA followed by Dunnett's t test (a-e).
| Salinomycin inhibits the proliferation and anchorage-independent growth of colorectal cancer cells
To 
| Salinomycin inhibits colorectal cancer cell stemness
Salinomycin is the first agent being identified as a selective inhibitor of CSCs (Gupta et al., 2009) . To explore the effect of salinomycin on the stemness of colorectal cancer cells, a sphere formation assay was performed. The colorectal cancer SW480 and HT29 cells were incubated with salinomycin at 0.5 and 1.0 μM for 1 week, and sphere formation was markedly inhibited after treatment with salinomycin ( Figure 6a,b) . The expression of stemness marker genes,
LGR5, CD44, and Sox2, was then examined by real-time PCR. The results showed that salinomycin decreased mRNA expression of these stemness marker genes (Figure 6c,d ). As expected, salinomycin significantly suppressed the protein levels of LGR5, CD44, and Sox2 in SW480 and HT29 cells (Figure 6e,f) . Having established that the expression of LGR5, CD44, and Sox2 genes could be up-regulated by activation of Wnt/β-catenin signalling (Barker et al., 2007; Van Raay et al., 2005; Wielenga et al., 1999) , salinomycin-induced were incubated with the indicated amounts of salinomycin for 24 hr and mRNA levels of stemness marker genes LGR5, CD44, and Sox2 were measured using real-time PCR. The data from five independent experiments are presented (n = 5). (e, f) SW480 (e) and HT29 (f) cells were incubated with the indicated amounts of salinomycin for 24 hr, and immunoblots were performed to detect the protein levels of stemness marker genes LGR5, CD44, and Sox2. The lower panel represents the densitometric quantification of the protein bands (n = 5). Values shown are means ± SD. *P < .05, significantly different from the vehicle control; one-way ANOVA followed by Dunnett's t test (a-f).
inhibition of stemness is most likely associated with its antagonistic effects on Wnt/β-catenin signalling.
| Salinomycin represses the growth of colorectal CSC xenografts
To evaluate the effect of salinomycin on the in vivo tumour-seeding ability of colorectal CSCs, CD44 high /CD133 high SW480 cells were implanted subcutaneously in NCG mice. Three days later, mice were randomly divided into two groups and treated with vehicle control and salinomycin for 1 month. Our results showed that tumour volumes in the salinomycin-treated group decreased significantly compared to the control group (Figure 7) , indicating that salinomycin could suppress the in vivo tumour-seeding ability of colorectal CSCs.
3.8 | Salinomycin attenuates colorectal tumour growth by blocking Wnt/β-catenin signalling in APC min/+ transgenic mice
To evaluate the in vivo efficacy of salinomycin against colorectal cancer, APC min/+ transgenic mice were employed. These animals bear a mutation at codon 850 of the APC gene. Over time, these mice spontaneously generate numerous adenomatous polyps in the small intestine and fewer polyps in the colon within several weeks of birth.
Eight-week-old mice were randomly divided into two groups and treated with either vehicle control or 5 mg·kg −1 salinomycin twice a week for 6 weeks. The mice were then killed, and the entire gastrointestinal tract was dissected out. Salinomycin treatment did not affect body weight of mice. Figure 8a ,b showed that salinomycin significantly reduced the size and number of colonic polyps (Figure 8a,b) . Histological analyses revealed that salinomycin treatment reduced tumour cell density ( Figure 8c ) and proliferation as indicated by Ki-67 staining (Figure 8d ). Immunohistochemical staining was used to detect the expression of Wnt signalling target molecules LGR5 and CD44.
Salinomycin-treated tumours showed significantly decreased levels of
LGR5 and CD44 compared with vehicle-treated tumours (Figure 8e,f) .
These results suggest that salinomycin suppresses colonic polyp growth by targeting Wnt signalling in APC min/+ mice.
3.9 | Salinomycin suppresses colorectal tumour growth and antagonizes β-catenin/TCF-mediated signalling in patient-derived colorectal tumour xenografts
The antitumour activity of salinomycin was assessed using five unique patient-derived colorectal tumour xenograft (PDTX) models. For each PDTX model, the patient-derived colorectal tumour pieces were implanted subcutaneously into the NPG mice. Expansion of the F1-F3 generations was carried out. The tumour pieces from PDTX (F3) were minced into small pieces and implanted into the NPG mice.
Tumour fragments from each PDTX were implanted into two mice.
After transplantation, mice were randomized into vehicle or salinomycin groups when tumour volumes reached about 50 mm 3 .
Mice were treated with vehicle or salinomycin at 5 mg·kg −1 every 3 days. Tumour size and body weight were monitored every 3 days.
Mice were killed 36 days after the treatment, and the tumours were lead to β-catenin stabilization and the formation of nuclear β-catenin/TCF4 complex (Nusse & Clevers, 2017) . Constitutive activation of Wnt signalling may favour the growth and maintenance of colorectal CSCs (Batlle & Clevers, 2017) . The β-catenin/TCF4 complex could also impose a crypt progenitor phenotype on colorectal cancer cells (van de Wetering et al., 2002) . Vermeulen et al. (2010) showed that colorectal CSCs exhibit high activity of the Wnt/β-catenin signalling pathway. Kanwar, Yu, Nautiyal, Patel, and Majumdar (2010) promise for successful therapy. However, no FDA-approved drugs are currently available that directly target the Wnt/β-catenin signalling pathway of CSCs for the treatment of colorectal cancer (Kahn, 2014; Lyou, Habowski, Chen, & Waterman, 2017) .
In this study, we have demonstrated that salinomycin suppressed colorectal cancer cell stemness by interfering β-catenin/TCF4E transcriptional complexes. Salinomycin also inhibited the growth of xenograft tumours derived by colorectal CSC population in mice. Our group and other groups have demonstrated that salinomycin could inhibit proximal Wnt signalling by blocking LRP6 phosphorylation and inducing its degradation (Dewangan et al., 2017; W. Lu & Li, 2014) . In our previous studies, micromolar concentrations of salinomycin were needed to block Wnt signalling induced by downstream activators, such as β-catenin, suggesting additional mechanisms must be involved in the inhibitory effect of salinomycin on Wnt signalling (D. . In colorectal cancers, mutations in APC and CTNNB1 genes are two major factors for aberrant activation of Wnt/β-catenin signalling. We thus explored the effect of salinomycin on the β-catenin/TCF4E transcriptional complex in colorectal cancer cells. Our results showed that salinomycin could disrupt association between β-catenin and TCF4E. Moreover, treatment with salinomycin suppressed the transcriptional activity of pDKK4-Luc reporter activated by either β-catenin 4A/LEF1 or β-catenin 4A/TCF4E in a dose-dependent fashion. Taken together, our results revealed a novel mechanism underlying the inhibitory effect of salinomycin on Wnt/β-catenin signalling in colorectal cancers. This study provides a rational basis for the therapeutic potential of salinomycin in cancers with mutational activation of the β-catenin destruction complex, such as colorectal carcinomas.
Although the colorectal cancer cell lines, SW480 and HCT116, contain mutated β-catenin, β-catenin exhibits a distinct subcellular localization in both cell lines. In HCT116 cells, β-catenin staining was strongest at the membrane with diffuse staining throughout the cytoplasm and nucleus, whereas β-catenin localized predominantly to the nucleus with weak cytoplasmic staining in SW480 cells, which is consistent with previous studies (Han et al., 2013) , suggesting that β-catenin subcellular distribution is cell line dependent. As β-catenin is known to interact with a number of proteins, β-catenin localization may be associated with expression and location of its interacting proteins. However, treatment with salinomycin had no effect on β-catenin subcellular localization in either cell line.
LGR5 is a target of Wnt/β-catenin signalling and considered a functional CSC marker in human colorectal cancers, which makes it an attractive target for the development of CSC-directed therapeutics (Hirsch & Ried, 2016; Shimokawa et al., 2017) .
LGR5 + colorectal cancer cells can serve as CSCs in growing cancer tissues. The expression of LGR5 is positively associated with poor prognosis in colorectal cancers (Chen et al., 2014) .
LGR5 high colorectal cancer cells exhibit higher clonogenic potential in vitro as well as higher tumourigenicity in vivo when compared to the LGR5 low cancer cells (Kemper et al., 2012) . In addition to LGR5, several other Wnt target genes have been proposed as colorectal CSC markers including CD44 and Sox2 (Voutsadakis, 2015) . In this study, we observed decreased expression of stemness marker genes LGR5, CD44, and Sox2 in colorectal cancer cells, in response to salinomycin treatment. Salinomycin also suppressed sphere formation of colorectal cancer cells. Importantly, salinomycin reduced tumour growth in colorectal CSC xenografts, APC min/+ mice, and patient-derived colorectal tumour xenografts and the expression of stemness marker genes LGR5 and CD44 at both mRNA and protein levels in APC min/+ mice and patient-derived colorectal tumour xenografts. These results indicated that salinomycin could selectively suppress colorectal CSCs through targeting Wnt/β-catenin signalling.
In a pilot study, salinomycin has been used for the treatment of patients with metastasized breast, ovarian, and head and neck cancer.
Salinomycin was intravenously administered every second day for 3 weeks, resulting in inhibition of disease progress for months without any serious long-term side effects (Naujokat & Steinhart, 2012) .
Salinomycin at 4 mg·kg −1 ·day −1 showed effective antitumour activity in a patient-derived mouse xenograft model of colorectal cancer (Klose et al., 2019) . Moreover, intraperitoneal injection of salinomycin at doses of 3 and 5 mg·kg −1 ·day −1 markedly suppressed tumour growth in human gastric cancer xenografts without causing obvious toxicities . However, adverse effects of salinomycin have also been observed. Ojo, Bhadauria, and Rath (2013) The major obstacle for clinical application of salinomycin is its systemic toxicity in vivo, with a narrow margin of safety (Dewangan et al., 2017) . Our results revealed great potential of salinomycin for treatment of colorectal cancer. Recently, site-specific colon drug delivery has been developed for improving treatment of colon-related diseases, while minimizing systemic toxicity (Amidon, Brown, & Dave, 2015) . The colon has several advantages for drug delivery, such as near neutral pH, long transit time, relatively low activity of proteolytic enzymes and increased responsiveness to absorption enhancers.
Approaches used for colon-specific delivery include pro-drugs, pH sensitive polymers, timed release delivery systems, and microbially degraded delivery systems (Philip & Philip, 2010) . We believe that colon-targeted drug delivery will considerably facilitate the clinical application of salinomycin to human colorectal cancer. Further studies are needed to develop colon-targeted salinomycin delivery systems for treatment of colorectal cancer.
